Impact of Hyperoncotic Albumin to Support Blood Loss Replacement
Status:
Completed
Trial end date:
2020-02-18
Target enrollment:
Participant gender:
Summary
Fluid treatment is usually performed with either balanced crystalloid fluids or iso-oncotic
colloids, (synthetic colloids, plasma and 5% albumin). Doubts have been raised about
synthetic colloids (impairment of renal function and coagulation), and the natural albumin
has been used more extensively. Albumin is the main protein responsible for plasma oncotic
pressure and its volume expansion effect. An alternative therapeutic option is the
mobilization of tissue fluid by infusing a small amount of hyper-oncotic fluid like the 20%
albumin solution (endogenous fluid recruitment).
The primary objective of this study is to test the effect of 20% albumin on plasma volume
expansion and fluid recruitment in the frame of blood loss replacement during cystectomy
using established fluid kinetic models.
The investigators expect that fluid replacement with crystalloid will be better sustained
intravascularly with the administration of 20% albumin and be able to recruit fluid into the
vascular compartment.